MarginsXMarginsX
Home › Markets › Health Care › REPL

Replimune Group Inc. (REPL)

REPL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$21.41
-2.19% on the day
Market cap
$2.0B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerREPL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001737953
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
15.0 months
$307.8M cash at September 30, 2026
Share count, 1 year
+20.9%
2025-11-03 to 2026-10-31 · +60.5% over 3 years
Going-concern doubt
Yes
10-Q filed October 28, 2026
Insider net buying, 12 months
-$1.9M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern."
10-Q 2026-10-28
Cash and burn$307.8M cash; operating cash flow -$61.4M a quarter.Report 2026-09-30
Shares outstanding94,800,404 (2026-10-31); 78,443,334 a year earlier; 59,059,343 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-10
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-07-28
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2027
2026-09-30
Not filed-$57.1M-$47.7M$307.8M$99.8MNeeds four quarters10-Q 2026-10-28
Q1 2027
2026-06-30
Not filed-$69.8M-$75.7M$185.4M$84.1MNeeds four quarters10-Q 2026-10-28
Q4 2026
2026-03-31
Not filed-$73.2M-$56.2M$209.0M$83.3MNeeds four quarters10-K 2026-06-29
Q3 2026
2025-12-31
Not filed-$70.9M-$66.0M$123.0M$47.6MNeeds four quarters10-Q 2026-02-03
Q2 2026
2025-09-30
Not filed-$83.1M-$81.2M$102.3M$47.2MNeeds four quarters10-Q 2026-10-28
Q1 2026
2025-06-30
Not filed-$86.7M-$77.0M$97.4M$46.8MNeeds four quarters10-Q 2026-10-28
Q4 2025
2025-03-31
Not filed-$74.1M-$53.7M$111.1M$46.4MNeeds four quarters10-K 2026-06-29
Q3 2025
2024-12-31
Not filed-$66.3M-$50.7M$172.2M$46.0MNeeds four quarters10-Q 2026-02-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-08-14
Latest annual report10-K2026-06-29
Latest quarterly / interim
FORM 10-Q/A
10-Q/A2026-11-06
Latest current report
FORM 8-K
8-K2026-10-28
Latest proxyDEFA14A2026-07-29

Source: SEC EDGAR submissions feed, 663 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.2%
1 month+80.8%
3 months+44.1%
Year to date+125.2%
1 year+143.8%
From 52-week high-6.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
BCRXBioCryst Pharmaceuticals Inc.$7.45-2.10%$1.9B
BEAMBeam Therapeutics Inc.$20.94-8.28%$2.2B
MAZEMaze Therapeutics Inc.$33.90-1.25%$1.9B
COAGHemab Therapeutics Holdings Inc.$39.05-4.42%$1.8B
RXRXRecursion Pharmaceuticals Inc.$2.90-8.79%$1.8B
WWBWindward Bio Group AG Common Shares$30.04+5.40%$1.7B
ALVOAlvotech$4.41+5.13%$1.7B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier